Stratified analysis of major clinicopathological parameters including sex, age, smoking status, EGFR status, and tumor‐node‐metastasis (TNM) stage confirmed a survival benefit for the CDSI‐high group (log‐rank test, p < 0.01; Figure S15C–G). Here, EGFR is linked to neoplasm.